Back to Search
Start Over
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
- Publication Year :
- 2004
-
Abstract
- Since interferon-α and imatinib (IM; STI571, Glivec, Gleevec) are effective for the treatment of chronic myeloid leukemia (CML), and their mechanisms of action are different, we designed an exploratory study investigating the effects of a standard IM dose (400 mg/d) and a variable pegylated interferon-α (PegIFN) dose (50 μg/wk, 100 μg/wk, and 150 μg/wk). The criteria for dose adjustment were designed so as to ensure the delivery of the IM dose and to protect life quality. There were 76 patients with previously untreated Philadelphia (Ph)–positive CML enrolled in the study. There were 3 patients who discontinued IM and 45 patients who discontinued PegIFN. The severity of adverse events increased with increasing PegIFN dose. The IM dose could be administered to the patients who were assigned to receive 50 μg/wk or 100 μg/wk PegIFN but not to those who were assigned to receive 150 μg/wk. The median administered dose of PegIFN ranged between 32 μg/wk and 36 μg/wk. The cytogenetic response was 70% complete (Ph-neg 100%) and 83% major (Ph-neg > 65%). The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies.
- Subjects :
- Male
PHILADELPHIA-CHROMOSOME
Biochemistry
Gastroenterology
Piperazines
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Chronic
BCR-ABL
Leukemia
CLINICAL RESISTANCE
CHRONIC MYELOGENOUS LEUKEMIA
Myeloid leukemia
TYROSINE KINASE INHIBITOR
ABL-POSITIVE CELLS
SEQUENCE BINDING-PROTEIN
FUSION GENE TRANSCRIPTS
CYTOGENETIC RESPONSES
ANTILEUKEMIC AGENTS
Hematology
Middle Aged
Recombinant Proteins
Toxicity
Benzamides
Imatinib Mesylate
Female
Drug
medicine.drug
Adult
medicine.medical_specialty
Immunology
Alpha interferon
Interferon alpha-2
Dose-Response Relationship
chronic myeloid leukemia
Aged
Dose-Response Relationship, Drug
Humans
Interferon-alpha
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pyrimidines
Internal medicine
medicine
Adverse effect
business.industry
Imatinib
Cell Biology
medicine.disease
Imatinib mesylate
imatinib
BCR-ABL Positive
recombinant alpha2b interferon
business
Chronic myelogenous leukemia
Myelogenous
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....213ab0a5c922d256eccc099c5fbf03e3